Latest Breaking News On - Lavoie health science - Page 10 : comparemela.com

AC Immune Initiates Clinical Study of First-in-class Diagnostic for Parkinson’s Disease February 08, 2021 07:00 ET | Source: AC Immune SA AC Immune SA Lausanne, SWITZERLAND LAUSANNE, Switzerland, Feb. 08, 2021 (GLOBE NEWSWIRE) AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that the first patient has been scanned in a first-in-human study of its novel diagnostic agent for Parkinson’s disease (PD). ACI-12589 is a next-generation positron emission tomography (PET) imaging tracer that has shown significant potential to reliably detect and map deposits of pathological alpha-synuclein protein in the brain, which is the major hallmark of PD. AC Immune expects to report the results of the study in Q3 2021. The clinical study is supported by the Michael J. Fox Foundation for Parkinson’s Research (MJFF), building on

Chris maggosAndrea pfeiferKatie gallagherEli lillyJoshua drummLavoie health scienceRoche groupJanssen pharmaceuticalsMichaelj fox foundation for parkinson researchNasdaq aciuAc immune saஆண்ட்ரியா பபெபேற்கேடீ கல்லாகர்எலி லில்லிஜோஷுவா டிரம்லாவோய் ஆரோக்கியம் அறிவியல்